Cleantech Co. Relaunches Pet Brand Under Its Own Control

1. BioLargo Inc. is a billboard sponsor of Streetwise Reports and pays SWR a monthly sponsorship fee between US$3,000 and US$6,000.
2. As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of BioLargo Inc.
3. Steve Sobek wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
4. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
5. This article does not constitute medical advice. Officers, employees, and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Disclosure for the quote from the John Newell article published on March 11, 2026

1. For the quoted article (published on March 11, 2026), BioLargo has paid Street Smart, an affiliate of Streetwise Reports, US$2,550.
2. Author Certification and Compensation: [John Newell of John Newell and Associates] was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Newell holds a Chartered Investment Management (CIM) designation (2015) and a  U.S. Portfolio Manager designation (2015). The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.

John Newell Disclaimer

As always it is important to note that investing in precious metals like silver carries risks, and market conditions can change violently with shock and awe tactics, that we have seen over the past 20 years. Before making any investment decisions, it's advisable consult with a financial advisor if needed. Also the practice of conducting thorough research and to consider your investment goals and risk tolerance.

2. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

BioLargo Inc. (BLGO:OTCQX) has unveiled plans to reintroduce its enormously popular CupriDyne®-based pet odor products to the consumer market under a new brand that has yet to be named, according to a July 13 release.

BioLargo is opting for a direct-to-consumer and online marketplace sales model, including platforms like Amazon, the release said. This approach emphasizes a digital-first marketing strategy that prioritizes targeted online advertising, allows for immediate tracking of marketing effectiveness, and maintains budget flexibility, rather than depending on expensive television campaigns.

"BioLargo's launch brings the CupriDyne® technology and BioLargo's original products back to consumers who loved them," the release said. 

"As a result, we have an opportunity to leverage the prior marketing success by introducing our own brand," said Joseph Provenzano, CEO of the new BioLargo consumer products subsidiary.

BioLargo said it sees this initial foray into pet odor control as the stepping stone to tapping into the broader home cleaning market. The company is positioning its products as superior solutions that eliminate rather than mask odors, a distinction that is readily apparent to consumers.

Pooph was launched in 2022 and became a runaway hit — driving Q1 2023 revenue up 288% year-over-year. It had expanded to thousands of stores and retail outlets, including Walmart, Amazon, and Chewy.

A series of business decisions by Pooph's management, including its abandonment of CupriDyne-formulated products, culminated in the foreclosure of its assets by its lender, board and CEO resignations, and what appears to be the cessation of business operations. 

The market for pet odor control and cleanup products in the U.S., as reported by Grand View Research, was valued at around US$6.47 billion in 2023, with projections suggesting it could rise to approximately US$8.87 billion by 2030.

'We Will Own the Brand'

Unlike the previous Pooph brand, BioLargo's new line will extend beyond pet products, using the launch as a foundation for introducing a wider range of CupriDyne products for home use. To support this recapture of a proven market, BioLargo has brought together a team of experts in branding, marketing, creative design, and channel sales, all of whom have notable experience in developing consumer brands within the pet and household sectors.

"It will be great to get back into the pet odor control and consumer products business," BioLargo Chief Executive Officer Dennis Calvert said. "We have seen what can be done, and this time we will own the brand and control the marketing and distribution."

A Year for Significant Agreements

It has been a busy year for the technology incubator, with significant agreements announced for its subsidiaries BioLargo Equipment Solutions & Technologies Inc. (BEST) and Clyra Medical Technologies Inc.

BEST signed a memorandum of understanding (MOU) with Aquatech, a leader in water purification. This collaboration aims to integrate and commercialize BioLargo's Aqueous Electrostatic Concentrator (AEC) technology, which effectively removes PFAS from water, with Aquatech’s advanced PFAS treatment systems. These systems are designed for full PFAS management with minimal waste, adhering to stringent regulatory standards for PFAS treatment in both public and private sectors.

Aquatech, which was named Water Technology Company of the Year at the 2025 Global Water Awards in Paris, brings a wealth of innovative water and wastewater management solutions to the partnership. Their technology suite includes membrane-based, thermal, biological, electrochemical, and ultrapure water treatment systems.

Tonya Chandler, president of BEST, expressed her enthusiasm about the partnership at the time, saying, "By partnering with Aquatech — one of the most respected and capable organizations in the global water treatment industry — we can significantly amplify the reach and impact of our Aqueous Electrostatic Concentrator technology."

Clyra entered into an exclusive distribution agreement with Al-Hikma FZCO, based in Dubai, United Arab Emirates. The agreement covers the commercialization of ViaCLYR™, an advanced wound irrigation solution, across the Gulf Cooperation Council, the Levant, North Africa, and several neighboring markets. ViaCLYR™, which utilizes Clyra's proprietary Clyrasept™ Copper-Iodine Complex Solution (CICS), is recognized for its broad-spectrum antimicrobial properties, biocompatibility, and support of natural healing processes.

The product is particularly effective in reducing wound fluid discharge, enhancing healing activity early in treatment, and significantly reducing wound size and depth, especially in pressure injuries. ViaCLYR™ is FDA 510(k) cleared for use in both acute and chronic wounds and burns, noted for its high antimicrobial activity and sustained efficacy for up to 72 hours.

These strategic initiatives by BioLargo through its subsidiaries underscore the company's commitment to forming strong alliances with industry leaders to expand market reach and accelerate the adoption of its clean technologies.

Expert Praises Co.'s Business Model

¹On March 11, Technical Analyst John Newell of John Newell & Associates provided a detailed review of BioLargo for Streetwise Reports, emphasizing the company's significant strides in the healthcare sector with Clyra.

Newell praised BioLargo's strategic approach of advancing its proprietary technologies through rigorous scientific validation and forming partnerships with established entities to enhance the distribution of its innovations. He noted that BioLargo's diverse portfolio includes solutions for advanced water treatment, environmental remediation, air quality control, energy storage, and medical technologies.

A key highlight in BioLargo's portfolio is Clyra, which specializes in copper-iodine antimicrobial solutions that remain effective for up to 72 hours and are non-cytotoxic, making them ideal for managing wounds and surgical infections, he said. Newell also pointed out that Clyra's flagship product, ViaCLYR™, has secured FDA 510(k) clearance, enabling its distribution through established medical device channels. The technology is supported by around 40 issued and pending patents and is available in various forms such as liquids, powders, hydrogels, and antimicrobial dressings.

In addition to its medical innovations, BioLargo is developing a long-duration energy storage system named the Cellinity™ battery. This system aims to address the limitations of traditional lithium-ion batteries for grid-scale applications by utilizing earth-abundant materials to extend battery life. The company intends to license this technology and collaborate with manufacturing facilities for its production.

Newell assigned a Speculative Buy rating to BioLargo, citing multiple potential catalysts across its technology platforms. He commended the company's methodical approach to commercialization and partnership, aligning well with the increasing demands for advanced healthcare solutions and sustainable energy storage.

Further updating BioLargo's progress, Oak Ridge Financial Analyst Richard Ryan described the company's business model on May 18 as a "hub and spoke format — invent/acquire a product, prototype/prove it out, partner with necessary third parties, and commercialize." Ryan reiterated his Buy rating on the stock, emphasizing that by commercializing technologies through operating subsidiaries, BioLargo effectively diversifies overall risk and maintains significant ownership in various segments while addressing diversified, high-growth end markets.

The Catalyst: Pet Odor, an Expanding Market

In the context of companies optimizing their production processes to cater to increasing market demands, the industry for pet odor control and cleanup products in the U.S. is experiencing significant growth. According to a report by Grand View Research, the market was valued at approximately US$6.47 billion in 2023. This sector is expected to continue its upward trajectory, with projections estimating that it will reach around US$8.87 billion by the year 2030. This expansion reflects a broader trend of escalating consumer demand, prompting companies to streamline their manufacturing strategies to meet these new market opportunities effectively.

"The increasing pet ownership and rising spending on pet care drive the market growth," Grand View said. "As more households in the U.S. welcome pets, the demand for products that maintain home hygiene and address pet-related odors has surged. Pet owners are more willing than ever to invest in high-quality solutions to manage pet waste and minimize unpleasant smells in their homes, fostering a strong demand for specialized odor control and clean-up products."

As of 2024, 66% of U.S. households (86.9 million) owned a pet, up from 56% in 1988, with many pet owners treating animals as family members, the report said. In fact, 97% of pet owners saw their pets as part of the family, and over half (51%) viewed them as equal to human family members. This trend further boosts the demand for the pet odor control and clean-up products industry.

"There has been a notable shift toward prioritizing home hygiene and cleanliness, especially in the wake of the COVID-19 pandemic," the report said. "Consumers are more aware of maintaining cleaner living environments, particularly in homes with pets. The concern over potential health issues from lingering pet odors and messes has prompted an increasing number of pet owners to adopt regular cleaning practices."

The global PFAS treatment market is projected to see substantial growth, with its value expected to increase from US$2.8 billion in 2025 to US$4.8 billion by 2033, achieving a compound annual growth rate (CAGR) of 7.1% during the period from 2026 to 2033, Grand View Research reported in other research.

And Future Market Insights forecasts a significant rise in the global market for anti-biofilm wound dressings, predicting a CAGR of 9.8% from 2025 to 2035. The market is anticipated to grow from US$943.5 million to US$2.4 billion over the decade, driven by an increase in surgical site infections, diabetic ulcers, and chronic wounds. In the United States, the market for these dressings is expected to grow at a CAGR of 9.3%, supported by an aging population, rising chronic wound prevalence, advancements in medical technology, and government health initiatives. These factors are enhancing the demand for advanced wound care solutions that effectively manage complex wounds and combat biofilm formation, thereby improving healing outcomes and reducing healthcare burdens.

Ownership and Share Structure²

About 14.07% of BioLargo is owned by insiders and management. About 0.04% is held by institutions with 13F-disclosed institutional holdings only. The rest, 85.89%, is retail.

Its market cap is US$36.74 million, with about 320.88 million shares outstanding. It trades in a 52-week range of US$0.10 and US$0.23.